AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39557557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 39557692 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic CSC
Number of subjects: 83
Study 39557730 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0
Study 39557997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-wake data combined with prior mood episode history
Number of subjects: 168
Study 39557997 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily circadian phase shifts
Number of subjects: 168
Study 39558017 — intervention group
Group type: EXPERIMENTAL
Intervention: TN-IBC tumors
Number of subjects: 0
Study 39558017 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive tumor-infiltrating immune components
Number of subjects: 0
Study 39558017 — intervention group
Group type: COMPARATOR
Intervention: TN-non-IBC tumors
Number of subjects: 0
Study 39558052 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured coordinative exercise programme focusing on locomotor and balance skills (30 min, 2 days a week for 8 weeks)
Number of subjects: 41
Study 39558052 — intervention group
Group type: COMPARATOR
Intervention: Normal curriculum (Control group)
Number of subjects: 41
Study 39558214 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support interventions targeting male partners via social events, home visits, and printed materials
Number of subjects: 408
Study 39558214 — intervention group
Group type: COMPARATOR
Intervention: Existing routine care
Number of subjects: 408
Study 39558214 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support interventions targeting male partners
Number of subjects: 408
Study 39558214 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 408
Study 39558280 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (G-ANC)
Number of subjects: 1761
Study 39558280 — intervention group
Group type: COMPARATOR
Intervention: Individual Antenatal Care (I-ANC)
Number of subjects: 1761
Study 39558302 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assessments via the patientMpower app including handheld spirometry and exercise tests.
Number of subjects: 350
Study 39558330 — intervention group
Group type: EXPERIMENTAL
Intervention: First-contact physiotherapy (FCP) model
Number of subjects: 60
Study 39558330 — intervention group
Group type: COMPARATOR
Intervention: Usual family physician (FP) care
Number of subjects: 60
Study 39558366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-reality (MixR) visualization during patient setup for 5 fractions of RT.
Number of subjects: 18
Study 39558366 — intervention group
Group type: COMPARATOR
Intervention: 3-point alignment during patient setup for 5 fractions of RT.
Number of subjects: 18
Study 39558366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-reality (MixR) visualization and 3-point alignment.
Number of subjects: 18
Study 39558368 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive Weight Bearing (PWB)
Number of subjects: 115
Study 39558368 — intervention group
Group type: COMPARATOR
Intervention: Restricted Weight Bearing (RWB)
Number of subjects: 115
Study 39558377 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) activated during intervention period
Number of subjects: 0
Study 39558377 — intervention group
Group type: COMPARATOR
Intervention: Routine care (CDSS deactivated) during control period
Number of subjects: 0
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA group (self-reported physical health assessed with CHQ)
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA group (self-reported psychosocial health assessed with CHQ)
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA group (self-reported physical disability assessed with CHAQ)
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor physical health (CHQ PhS < 40)
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-related pain
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's global assessment of disease impact on wellbeing
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active disease according to Wallace
Number of subjects: 221
Study 39558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported global assessment of disease activity
Number of subjects: 221
Study 39558411 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched population-based controls)
Number of subjects: 221
Study 39558601 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of analgesics
Number of subjects: 21
Study 39558828 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized medical monitoring of local radiological/functional imaging reports
Number of subjects: 640
Study 39558828 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 640
Study 39558901 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2-3 mg/day (flexible dose)
Number of subjects: 0
Study 39558901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39559133 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal resection Turbinoplasty
Number of subjects: 40
Study 39559133 — intervention group
Group type: COMPARATOR
Intervention: Partial inferior turbinectomy
Number of subjects: 40
Study 39559450 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of comorbidities
Number of subjects: 830
Study 39559450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension
Number of subjects: 830
Study 39559450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body mass index
Number of subjects: 830
Study 39559450 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 830
Study 39559450 — intervention group
Group type: EXPERIMENTAL
Intervention: 3, 4 or >5 comorbidities
Number of subjects: 830
Study 39559491 — intervention group
Group type: EXPERIMENTAL
Intervention: RegEx algorithm for patient identification
Number of subjects: 0
Study 39559491 — intervention group
Group type: COMPARATOR
Intervention: Manual review
Number of subjects: 0
Study 39559532 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscopy with a tip-bendable suction ureteral access sheath (f-URS with S-UAS)
Number of subjects: 720
Study 39559532 — intervention group
Group type: COMPARATOR
Intervention: Mini-percutaneous nephrolithotomy (mPCNL)
Number of subjects: 720
Study 39559856 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBOTRAP device
Number of subjects: 997
Study 39559990 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP
Number of subjects: 0
Study 39559990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo
Number of subjects: 0
Study 39559990 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39560075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (high-dose greater than 1000 mg/day)
Number of subjects: 16325
Study 39560363 — intervention group
Group type: EXPERIMENTAL
Intervention: mLab App
Number of subjects: 525
Study 39560363 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 525
Study 39560398 — intervention group
Group type: EXPERIMENTAL
Intervention: CIH therapies (n = 140)
Number of subjects: 280
Study 39560398 — intervention group
Group type: COMPARATOR
Intervention: SRC (n = 140)
Number of subjects: 280
Study 39560548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of PG201 (405.4 mg) and celecoxib (100 mg)
Number of subjects: 46
Study 39560548 — intervention group
Group type: COMPARATOR
Intervention: Individual formulations of PG201 and celecoxib
Number of subjects: 46
Study 39560548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of PG201 and celecoxib
Number of subjects: 46
Study 39560548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FDC and individual formulations
Number of subjects: 46
Study 39560745 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified meal announcement (SMA)
Number of subjects: 46
Study 39560745 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate counting (CC)
Number of subjects: 46
Study 39560745 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA
Number of subjects: 46
Study 39560745 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 46
Study 39560771 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose of enoxaparin starting at 0.5 mg/kg adjusted to anti-Xa range of 0.2-0.5 IU/mL for older children
Number of subjects: 258
Study 39560771 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of enoxaparin starting at 1.5 mg/kg adjusted to anti-Xa range of greater than 0.5-1.0 IU/mL or 0.2-0.5 IU/mL for infants
Number of subjects: 258
Study 39560771 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no enoxaparin)
Number of subjects: 258
Study 39560777 — intervention group
Group type: COMPARATOR
Intervention: 2021
Number of subjects: 72242
Study 39560777 — intervention group
Group type: COMPARATOR
Intervention: 2022
Number of subjects: 72242
Study 39560860 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseodensification technique
Number of subjects: 32
Study 39560862 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (150 mg bid for 3 days on/4 days off) plus Durvalumab (1500 mg Q4W)
Number of subjects: 55
Study 39560862 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (300 mg qd for 5 days on/2 days off) plus Durvalumab (1500 mg Q4W)
Number of subjects: 55
Study 39560862 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib plus Durvalumab
Number of subjects: 55
Study 39560984 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, in-language Diabetes Prevention Program (DPP) videos (2-3 per week for 12 weeks) and biweekly phone calls from bilingual staff, plus produce for 10 weeks from a community-supported agriculture program
Number of subjects: 150
Study 39560984 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 150
Study 39561129 — intervention group
Group type: EXPERIMENTAL
Intervention: Call for Life-Interactive Voice Response with standard of care
Number of subjects: 206
Study 39561129 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 206
Study 39561184 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (ALB)
Number of subjects: 94
Study 39561184 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole/ivermectin (ALB/IVM) combinations
Number of subjects: 94
Study 39561184 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz (K-K)
Number of subjects: 94
Study 39561184 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 94
Study 39561225 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg biweekly in addition to high-intensity statins
Number of subjects: 300
Study 39561225 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to high-intensity statins
Number of subjects: 300
Study 39561235 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 849
Study 39561235 — intervention group
Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 849
Study 39561235 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock in last 90 days
Number of subjects: 849
Study 39561235 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of life
Number of subjects: 849
Study 39561235 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator shocks
Number of subjects: 849
Study 39561281 — intervention group
Group type: EXPERIMENTAL
Intervention: dVHH NS7CAR-T cells (dosage levels: 5×10^5/kg and 1×10^6/kg)
Number of subjects: 10
Study 39561281 — intervention group
Group type: EXPERIMENTAL
Intervention: dVHH NS7CAR-T cells
Number of subjects: 10
Study 39561359 — intervention group
Group type: EXPERIMENTAL
Intervention: AI predictive tool using recurrent neural networks (RNN)
Number of subjects: 6125
Study 39561359 — intervention group
Group type: EXPERIMENTAL
Intervention: AI predictive tool using light gradient boosting machine (LightGBM)
Number of subjects: 6125
Study 39561359 — intervention group
Group type: EXPERIMENTAL
Intervention: AI predictive tool
Number of subjects: 6125
Study 39561359 — intervention group
Group type: EXPERIMENTAL
Intervention: Key predictive features
Number of subjects: 6125
Study 39561384 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin reverse thermal gel)
Number of subjects: 71
Study 39561465 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 192
Study 39561689 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-enriched soy milk (2 g/day)
Number of subjects: 13
Study 39561689 — intervention group
Group type: COMPARATOR
Intervention: Normal soy milk (control group)
Number of subjects: 13
Study 39561769 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous LEPR variants
Number of subjects: 10000
Study 39561769 — intervention group
Group type: COMPARATOR
Intervention: Exome data from 200,000 individuals in the UK Biobank
Number of subjects: 10000
Study 39561881 — intervention group
Group type: EXPERIMENTAL
Intervention: Azvudine
Number of subjects: 5735
Study 39561881 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 5735
Study 39562048 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based assay for EAC and BE using six miRNAs (miR-106b, miR-146a, miR-15a, miR-18a, miR-21, miR-93)
Number of subjects: 0
Study 39562048 — intervention group
Group type: COMPARATOR
Intervention: Non-disease controls
Number of subjects: 0
Study 39562051 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education and motivational interviewing program based on the IMB model for 12 weeks
Number of subjects: 60
Study 39562051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 39562219 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended bleaching tray (3 mm)
Number of subjects: 72
Study 39562219 — intervention group
Group type: COMPARATOR
Intervention: Nonextended bleaching tray (1 mm)
Number of subjects: 72
Study 39562382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoidan
Number of subjects: 0
Study 39562414 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Methanobrevibacter (Archaea)
Number of subjects: 25
Study 39562414 — intervention group
Group type: COMPARATOR
Intervention: High TMAO plasma levels
Number of subjects: 25
Study 39562421 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Number of subjects: 16
Study 39562421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein
Number of subjects: 16
Study 39562421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispectral imaging
Number of subjects: 16
Study 39562502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower chromosome fragility
Number of subjects: 227
Study 39562502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations leading to mutant FANCA protein expression (genetic hypomorphism)
Number of subjects: 227
Study 39562502 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic mutations in FANCD2 (mainly hypomorphic mutations)
Number of subjects: 227
Study 39562502 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic mutations in FANCG
Number of subjects: 227
Study 39563035 — intervention group
Group type: EXPERIMENTAL
Intervention: ARI0003 (anti-CD19/BCMA CAR-T cells)
Number of subjects: 0
Study 39563035 — intervention group
Group type: COMPARATOR
Intervention: anti-CD19 CAR-T cells
Number of subjects: 0
Study 39563035 — intervention group
Group type: COMPARATOR
Intervention: anti-CD19/CD20 or anti-CD19/CD22 dual targeting
Number of subjects: 0
Study 39563094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399
Study 39563102 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Minute Step Test (2MST)
Number of subjects: 55
Study 39563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Any human papillomavirus infection at mid-gestation
Number of subjects: 950
Study 39563227 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus infection at mid-gestation
Number of subjects: 950
Study 39563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus genotype 16 infection at mid-gestation
Number of subjects: 950
Study 39563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple genotype infections at mid-gestation
Number of subjects: 950
Study 39563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Persisting infections during pregnancy
Number of subjects: 950
Study 39563247 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Health Project (CHP)
Number of subjects: 0
Study 39563247 — intervention group
Group type: COMPARATOR
Intervention: Couples HIV testing and counseling (CHTC)
Number of subjects: 0
Study 39563248 — intervention group
Group type: EXPERIMENTAL
Intervention: TES: Vira smartphone app
Number of subjects: 130
Study 39563248 — intervention group
Group type: COMPARATOR
Intervention: Control: Mood Education mobile app (ME)
Number of subjects: 130
Study 39563299 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme (THP) intervention
Number of subjects: 0
Study 39563311 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise using elastic bands (performed exercise dose measured in repetitions/week)
Number of subjects: 94
Study 39563311 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise using elastic bands
Number of subjects: 94
Study 39563319 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP-facilitated MARPE (MMG)
Number of subjects: 48
Study 39563319 — intervention group
Group type: COMPARATOR
Intervention: MARPE without MOP (NMG)
Number of subjects: 48
Study 39563319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MMG and NMG)
Number of subjects: 48
Study 39563407 — intervention group
Group type: EXPERIMENTAL
Intervention: HABITs + Texts
Number of subjects: 160
Study 39563407 — intervention group
Group type: COMPARATOR
Intervention: HABITs
Number of subjects: 160
Study 39563457 — intervention group
Group type: EXPERIMENTAL
Intervention: J8-K4S2
Number of subjects: 30
Study 39563457 — intervention group
Group type: EXPERIMENTAL
Intervention: p*17-K4S2
Number of subjects: 30
Study 39563457 — intervention group
Group type: COMPARATOR
Intervention: Comparator (rabies vaccine)
Number of subjects: 30
Study 39563465 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-FORT intervention (7 consecutive weeks of virtual group therapy and homework)
Number of subjects: 36
Study 39563465 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-FORT intervention
Number of subjects: 36
Study 39563465 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (care as usual)
Number of subjects: 36
Study 39563886 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies based on signaling pathways (e.g., BCR, PI3K/AKT/mTOR, NF-kB, JAK/STAT)
Number of subjects: 0
Study 39564145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane ophthalmic drop, 4 times daily for 8 weeks
Number of subjects: 1217
Study 39564145 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic saline control, 4 times daily for 8 weeks
Number of subjects: 1217
Study 39564355 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaverse-based multimodal rehabilitation intervention over a 4-week period
Number of subjects: 60
Study 39564355 — intervention group
Group type: COMPARATOR
Intervention: Conventional care group
Number of subjects: 60
Study 39565030 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment
Number of subjects: 3608
Study 39565030 — intervention group
Group type: COMPARATOR
Intervention: 14 days of antibiotic treatment
Number of subjects: 3608
Study 39565030 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment (per-protocol analysis)
Number of subjects: 3608
Study 39565030 — intervention group
Group type: COMPARATOR
Intervention: 14 days of antibiotic treatment (per-protocol analysis)
Number of subjects: 3608
Study 39565096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led mobile app (NL-Mapp) intervention
Number of subjects: 90
Study 39565096 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 90
Study 39565228 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab (SEC) 300 mg s.c. administered regularly until week 16, followed by randomization to SEC or placebo up to week 32.
Number of subjects: 0
Study 39565228 — intervention group
Group type: COMPARATOR
Intervention: Placebo after SEC treatment.
Number of subjects: 0
Study 39565228 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (SEC) treatment.
Number of subjects: 0
Study 39565276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Inspiratory Muscle Training (Hi-IMT)
Number of subjects: 90
Study 39565276 — intervention group
Group type: COMPARATOR
Intervention: Sham Low-Intensity Inspiratory Muscle Training (Lo-IMT)
Number of subjects: 90
Study 39565449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (100 mg/day for 4 weeks or until discharge)
Number of subjects: 60
Study 39565449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 39565495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vepdegestrant 200 mg once daily (QD)
Number of subjects: 6
Study 39565495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vepdegestrant 200 mg QD
Number of subjects: 6
Study 39565523 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLU-C10D
Number of subjects: 435
Study 39565523 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 435
Study 39565570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab plus radium-223
Number of subjects: 21
Study 39565570 — intervention group
Group type: COMPARATOR
Intervention: Radium-223 alone
Number of subjects: 21
Study 39565635 — intervention group
Group type: EXPERIMENTAL
Intervention: ATEV (Acellular Tissue Engineered Vessel)
Number of subjects: 86
Study 39565635 — intervention group
Group type: COMPARATOR
Intervention: Synthetic graft benchmarks
Number of subjects: 86